Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript

Evotec SE (NASDAQ:EVO) Q4 2023 Earnings Call Transcript April 24, 2024

Evotec SE misses on earnings expectations. Reported EPS is $-0.05 EPS, expectations were $-0.03333. Evotec SE isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here).

Operator: Ladies and gentlemen, welcome to the Evotec SE Annual Report 2023 Conference Call. I’m Moritz Nikolaus, call operator. I would like to remind you that all participants will be in a listen-only mode, and the conference is being recorded. [Operator Instructions] At this time, it’s my pleasure to hand over to Volker Braun, Head of IR and ESG. Please go ahead, sir.

Volker Braun: Thank you, Moritz. And good day, good morning to all of you on the call. I’m sure you all have seen our press release on our 2023 results this morning, as well as the announcement last night on the appointment of Dr. Christian Wojczewski, who will be our new CEO of 1st of July. This development is the reason why we also have Iris Löw-Friedrich, our Chairwoman of the Supervisory Board, with us on the call today. But before we go there, it’s my obligation to familiarize you with the cautionary language we have outlined on Page 2. But now, without further ado, I would like to hand over to Iris. Please, Iris, the floor is yours.

Iris Löw-Friedrich: Yeah, Volker, thank you very much. And very warm welcome to all of you also from my side. We are ready to win the future for Evotec. Our core offerings are in high demand. Our business model is solid. Business is growing. We focus on profitability. And most importantly, we have a super strong team in place, and we are strengthening the leadership in Evotec further. And that’s the reason why I participate as the Chair of the Supervisory Board in a regular full year results call today. So with me today, Laetitia Rouxel, our Chief Financial Officer, who will cover the review on Evotec’s performance in 2023; followed by Matthias Evers, our Chief Business Officer, who will guide you through the rationale and the details of the reset of the company’s priorities for the coming year.

Our Chief Operating Officer, Craig Johnston; and our Chief Scientific Officer, Cord Dohrmann, will stand by to answer any questions you may want to address to them during the Q&A session. I have the duty to excuse, Mario Polywka, our Interim CEO, who is ill today, and unfortunately not able to participate in this call. So we send him our best wishes for recovery. I would like to deeply thank, Laetitia and Matthias, for stepping in for Mario on short notice. Before we move to operational topics, please allow me to share the good news on the Supervisory Board’s actions taking during the last close to 4 months. These efforts have led to the successful appointment of Dr. Christian Wojczewski, as our new CEO; and of Aurélie Dalbiez, as the newly created management board role of a Chief People Officer.

A few words about the new CEO. The Evotec turnaround starts with a high-performing team at the top. If I can speak about myself, but I know it’s also on behalf of the entire Supervisory Board, we all feel highly accountable to drive the reset of the company, starting with the best leader for the further evolution of Evotec with all the relevant stakeholders in mind. We are confident that we have made the right choice. We reviewed a wide slate of diverse internal and external candidates. We ran a structured interview process with more than 10 candidates and an in-depth in-person workshop with the 5 finalists. We pressure tested their approach to our business. We tested their strategic competency, their operational execution, their experience, and, of course, their leadership skills.

The appointment of Christian Wojczewski, as the new CEO of Evotec underscores our determination to drive a turnaround with a focus on profitability, efficiency, and highest performance, while of course we need to further evolve the excellent science in all businesses of Evotec. Christian Wojczewski comes with an impressive track record of successful transformational change in the life sciences business, the creation of high-performing organizations, and the clear focus on profitable growth. He demonstrated his strategic and operational leadership skills at the Executive Board of Linde, where he transformed the healthcare business into a global market leader with sales tripled and leading EBITDA margins. As the CEO of Mediq, he transformed the business from a distribution model to a service model with streamlined business processes, a focused portfolio and a high performance culture, all of this resulted in a turnaround towards profitable growth.

And these experiences will of course benefit Evotec greatly. So Christian is an accomplished leader who will make Evotec fit for a prosperous future. Next slide please. The management team has further strengthened with the addition of Aurélie Dalbiez, our first Chief People Officer. Aurélie joins us from Corbion, where she was the Chief Human Resources Officer. She comes with a longstanding career in talent-related positions. Aurélie will ensure the alignment of the Evotec’s people strategy and cultural evolution with the company strategy, while she will further evolve sustainability, first and foremost, creating an inclusive culture with proficient teamwork, innovation and customer orientation top of mind. Aurélie was chosen following another intense search process, which illustrated once more that Evotec is highly attractive for eminent leaders.

The combination of heightened attention to our people in Evotec with our high-quality science and innovation and with a performance-oriented business model will make us unique and, I’m deeply convinced, finally unbeatable. I recognize that we have a lot of work to do to achieve this and the reset has started. And with that, it’s my pleasure to hand over to Laetitia to familiarize you all with the details of Evotec’s performance in 2023 and the most recent developments.

Laetitia Rouxel: Thank you, Iris, and a warm welcome to all of you for joining us today to delve into our performance of the financial year 2023. It was a very intense year for Evotec. It started off extremely strong. We expanded and extended two collaborations with BMS and were able to win Janssen as a strong partner in the field of oncology. On April 6, we have been hit by the cyber incident that had led to €70 million missed revenue in 2023, largely in Q2. Despite all the challenges, we could celebrate successes with Just signing a technology alliance with Sandoz in May, validating the Just value proposition. Through our focused efforts, we have seen a strong recovery of the business in Q3, coming back to 80% of operations with a strong revenue growth of 13%.

In Q4, we faced a challenging market environment that was still masked by positive contribution from the fading cyber incident recovery. With that said, let us take a look at the full year results. We are pleased to report that our revised guidance for 2023 was fully achieved. Our Group revenues for the year were €781.4 million in the upper range of €750 million to €790 million as we had projected. Unpartnered R&D expenses totaled €64.8 million falling within our estimated range of €60 million to €70 million and reflected our continued focus on innovation and growth. The adjusted EBITDA for the year was €66.4 million meeting our guidance range of €60 million to €80 million. As just mentioned, we achieved €781.4 million revenue in 2023, a solid 4% increase compared to the previous year, and despite facing significant operational cyber-related impacts for the majority of Q2.

These headwinds mainly in our development and Cyprotex business were more than offset by the strong performance from our key strategic partnerships. Notably, revenue from Just-Evotec Biologics reached €108.4 million reflecting a remarkable rose of more than 110% compared to the prior year. This substantial increase underscores the success of our partnerships, especially with Sandoz and the strengthening of our portfolio. Our gross margin experienced some pressure, declining slightly to 22.6% from 23.2% due to the cyber incident, development market challenges, the ramp-up of capacity at Just-Evotec Biologics, and excluding Just gross margin was 27%. We remain committed to investing in the future with unpartnered R&D expenses of €64.8 million as we continue to drive innovation.

Adjusted Group EBITDA for the year were €66.4 million, marking a 34% decline from last year, largely due to non-recoverable business and reduced capacity utilization in Q2. One from cyber-related costs included in EBITDA represents €26.5 million. Excluding Just-Biologics, Adjusted Group EBITDA would be at €72.7 million with Execute absorbing most of cyber-related expenses. Furthermore, we are proud to have made significant strides in sustainability, reducing our Scope 1 and 2 emissions by 29% to 27,480 tons CO2 equivalent as we are growing greener. As outlined on the previous slide, Innovate has an excellent growth of more than 30% despite the challenges we faced. Main drivers for this positive development were the extension and expansion of contracts with BMS in neurodegeneration as well as in target protein degradation.

Also, new collaboration with Janssen in cell therapy as well as the tech alliance with Sandoz demonstrates that demand for differentiated and paradigm shifting technology platform is very robust and a truly distinctive factor in the overall challenging market. As we indicate here on the slide as well, our full sales funnel has grown significantly across shared R&D and particularly also since validation of our Just-Evotec Biologics CDMO offering. A substantial part of these opportunities sits in early final stages and we are working hard on conversion, winning this new partnership and translating this into revenues in later 2024 and 2025. Total Execute segment including intersegment revenue had stable revenues at €738.7 million, driven by the Sandoz collaboration yielding a gross margin of 20.9%.

Innovate segment revenue was €266.9 million in 2023 reflecting a gross margin of 30.8%. Despite the strong challenges, this year we achieved a 4% organic growth in Group revenues. As mentioned, Just-Evotec Biologics revenue rose by 111% demonstrating exceptional growth driven by the collaboration with Sandoz. Innovate reported a 30% increase showing strong momentum attributable mainly to BMS and other key strategic partnerships. As we mentioned in our previous calls, Execute was mostly adversely impacted by the voluntary shutdown of our operations in response to the cyber incident and the softening market towards the end of the year. However, overall segment revenues for Execute grew over year-over-year, inclusive of intersegment revenues, as we reallocated resources towards supporting high value partnerships within the Innovate segment.

Despite a lower contribution from milestones, upfront and licenses, our diverse business model continues to show its robustness, maintaining a solid gross margin of 27%, excluding Just-Biologics. Focusing on Q4, Group revenue were €201.3 million, reflecting a 16.4% decline compared to the strong comparable base in 2022. While in a challenging market, positive contribution were related to BMS’ Celgene programs and the successful delivery of work packages as part of our new technology partnership with Sandoz. It’s important to note that the revenue mix had a very different structure as opposed to Q4 2022. Contribution for milestone to the tune of €17.7 million were significant in the last year’s quarter, while Q4 2023 was a rather modest period with milestones and upfront payments reaching €1.2 million.

Also Q4 2022 saw the one-off effect of royalty income from [SK bio] [ph] of about €2 million, which had a positive effect on margins too. Gross margin contracted to 18.7% compared to a robust quarter of previous year influenced by the overhang of low sales during the cyber incident, challenging market conditions, unfavorable sales mix and reduced milestones upfront and licenses payment and ramp up of the cost of Just-Evotec Biologics also impact the margin while showing our commitment for the future growth. Switching now our focus to cost management. R&D expenses were €20.2 million for the quarter, 5.4% lower than the comparable prior year period. This decrease was influenced by a temporary reduction in R&D cost stem from the cyber incident, but still indicate our strong dedication to innovation.

Our Adjusted Group EBITDA, which does not include external one of cyber-related cost for the last quarter of 2023 represents €16.5 million compared to €57.1 million in Q4 2022. While the gap is significant, I want to recall that Q4 2022 was the strongest quarter in Evotec history by a wide margin and year-over-year comparison needs to be seen in that context. The negative development in Q4 2023 triggered the need for a comprehensive review of the business. Together with Mario, we therefore initiated an in-depth analysis to assess measures needed to foster a sustainable, profitable growth in the future. With that, I would like to hand over to Matthias to share with you our thought process, findings and decision on actions to be taken.

Matthias Evers: Great. Thank you very much, Laetitia. Good morning, good afternoon, also from my side. Basically, as information about the developments in Q4 materialized, we launched this structured performance review, looking closely at the external environment as well as our inner workings. Let me share with you the top level results today in form of a SWOT analysis. And I will basically walk from the bottom to the top. So I start with the more external-oriented dimensions, opportunities and threats, and then to the strengths and weaknesses. Opportunities. And I start, therefore, for hopefully an obvious reason, because we face very strong demand and opportunities in terms of expanding our human data-centric multiomics approach to R&D.

Here, I mentioned the molecular patient database, which is at the heart of our PanOmics efforts. Clearly, and it has been behind the numbers, and my colleague Laetitia mentioned it, we have seen the commercial validation of Just-Evotec Biologics. We have seen an increasing demand. We have fully capitalized on it. We have a full sales order book. We are quite careful to describe the U.S. BIO-SECURE bill as an opportunity. We just want to signal we are here for the partners in the U.S. to collaborate with them with our global footprint. When it comes to threats, we describe the market at this point of time as a bias market with more challenging dynamics. I will go later in the presentation a little bit into the drivers, but it’s fair to say that particular for biotech companies, 2023 and now 2024 has been a difficult environment.

So we see a market recovery towards 2025, and that is, of course, as stated a threat. Let me move to our strengths. And here I want to be very clear that our scientific expertise combined with our track record, our differentiating capabilities on our integrated end-to-end platform lead to very strong demand that has led to double-digit growth has led to an expansion of our sales pipeline. We see a demand for this, including and leading to customer retention rates north of 90%. There is clearly a weakness identified, and I will come also in this presentation with our response against it. But to put plainly, we have found an internal complexity and operational inefficiencies that we are targeting now head on. When it comes to our capacity, there’s a temporary mismatch because we have seen the softening in the more transactional parts of our business.

So we have to call it temporary, something that we can repair quite quickly and we have a plan for that. With that, let me move to the next chapter of this presentation, which is about the priority reset we are introducing here today. And then Laetitia will continue later on guidance and outlook. As we talk about new priorities, I think it’s very important we put those into external context. As promised, I want to talk a little bit more about how we see the market today. Clearly there is demand, but we have seen cost containment on the biotech side, on the big pharma side, and what is for us relevant to say, we have less Series A, Series B events, and so roughly 40% of our business sits in biotech, and that share has gone down a bit, because there are simply less new starts in the biotech segment.

Overall, I think the market summary is that the effort towards conversion and towards winning business is higher, and we have seen that also in our peer group performance. In summary, I would conclude that we see green shots in the market, like competitors, we see that more towards the end of the year into 2025, and see this type of market environment as a context for the priorities I’m now introducing. We as an organization clearly commit to three priorities under the header towards profitable growth. So we are clearly a company growing at double-digit following this demand, but this growth has to be profitable. Priority number one, clearly, and I will detail it in a second, deals with our focusing on what we are good at and driving smart partnering.

Secondly, we are now adjusting our organization and footprint. And number three, we put the strongest possible team in place for today focusing on the management board, but of course going beyond. Now, indeed, let me double click a little bit into the first priority. You see here two illustrative analyses of where the money is going in deal making: one by therapeutic area; one by modality. And in short, it’s fair to say we have massive opportunities as we are well aligned against these areas, let’s say, in oncology, neurology, cardiovascular, or in the core modalities. What we are doing here is doubling down. And I would call these actions our growth program, because it’s a careful alignment. So to become a little more specific, an example is for instance, metabolic obesity, that we align our efforts in R&D, our strengths against where the market demand is, we clearly double down on key modalities.

And that has to be seen also in the context of Just-Evotec Biologics, where we have a fantastic offering for complex biotherapeutics. And we focus on what we get very strong feedback on, our flexible partnering that we offer win-win models from our partners from foundation to biotech to big pharma, but clearly prioritizing that our models where we cover our R&D funding and generate upsides. With that, let me hand over to you, Laetitia, to detail the restructuring parts of our priorities.

Laetitia Rouxel: Thank you, Matthias. Resetting our focus and offering to a changing environment comes with the need to adjust our organization and footprint to the new realities. Our restructuring focuses our own three targets: one, optimization of our organizational structure and operational model; two, adjustment of our footprint and capacity optimization; and three, as well as improving the efficiency of our enabling function. We completed the diagnostic, and we are now working with full effort on multiple key levers. As a result, we expect to generate visible margin improvements over the coming years. The measures identified at this stage should result in an annualized benefit on EBITDA of more than €40 million. For 2024, we will see a pro rata effect and expect to see a first full impact by 2025 I would highlight our effort in three key levers there.

In procurement, for instance, we aim to leverage our global scale, harmonize and optimize pricing for the good and services we are buying, and rationalize diversity in what we buy. They may be low-hanging-fruit, but they require flawless execution that we commit to. Second, focusing on the right sizing capacity with the right expertise. And thirdly, simplify internal structure like the new segment reporting, which brings us to the next slide where we are grouping the former innovate and execute offering, excluding Just-Biologics into our end-to-end platform serving 500 plus partners. This segment will be called shared R&D. With that, we reduced the recognition of intersegment revenues of meanwhile more than €200 million. This will reduce redundancies of internal structures and will lead to more efficient and linear processes.

The new segment reporting will also give better transparency to Just-Biologics in line with what we heard during our past interactions with you. The new structure will be in place as of Q1 2024 reporting and we will provide more detailed information on comparable numbers versus 2023 in due course. Talking about the start of the year, which in essence saw a continuation of the patterns we saw during Q4, let me share a view on our expectations for 2024. At this stage, we expect revenue grows to remain robust at low-double-digit rates, while the mix is set to change versus prior years. Just-Biologics as well as differentiated offerings will drive the business, while more transactional businesses are likely facing a challenging environment this year.

Future growth, more favorable business mix, as well as our efficiency improvement measures on EBITDA are the basis to assume that EBITDA will grow middle-double-digit. Further details of refined guidance will be dependent on the overall market environment, win rates of existing leads and new collaboration, and phasing of the efficiency gains in 2024. To recap, I want to emphasize on our strengths in revenue growth, while we focus on driving profitability. The structure of our revenue mix suggests that growth at Just-Evotec Biologics will be faster than in shared R&D in the coming years. At this stage, we expect a stable growth of revenue related to milestone and royalty payments, given the growing breadth and depth of our portfolio. For 2025, we expect the double-digit revenue growth at reach to continue bringing us into the ballpark of €1 billion revenue.

In general, we anticipate the mid-term growth profile to remain similar to patterns in the past. As we are here for the long-term, we expect a more favorable revenue mix and more efficient structures to build the basis for the very profitable growth. The details of this new midterm outlook will be assessed together with Christian and we plan to provide the first update also in August. As Iris mentioned already, we can say that our Supervisory Board successfully executed with regard to priority three on our list, which is strengthening our internal team and we look forward to working together with Christian and Aurélie to shape Evotec’s sustainable growth path into the future. They represent two important additions as an example of how important it is for us to focus on talents and fostering expertise at Evotec.

Here are the next important dates of our financial communication in 2024. And to conclude, we have fully met our 2023 revised guidance. We confirm double-digit top-line growth for 2024. We confirm mid-double-digit EBITDA growth for 2024. And we continue to outpace revenue growth in the years to come. We are resetting and right-sizing our operations to drastically enhance profitability. And finally, we are looking forward to driving the next phase with Christian and Aurélie on board.

Volker Braun: Thank you, Laetitia and team. We are now looking forward to taking the questions from people attending the call. And I ask, Moritz, to start the Q&A session now, please.

See also 20 Biggest Gold Companies in Australia in 2024 and 20 Countries That Increased Oil Production the Most in A Decade.

Q&A Session

Operator: Ladies and gentlemen, at this time we begin the question-and-answer session. [Operator Instructions] And the first question comes from Peter Verdult from Citi. Please go ahead.

Peter Verdult: Thank you. Peter Verdult here from Citi. Lots to discuss. I’ll restrict myself, I beg your patience, to three questions around the topics to cover. Maybe just starting with Laetitia. This will also take the time on the guidance you provided for 2024 and some of the comments you’re making about 2025. I try and quantify it, it looks like you’re promising the market at least €100 million EBITDA in 2024 and €200 million plus in 2025. So the key question for myself, as well as share [ph] I can guess what you expected today, is just assessing when any form or types of risks here. So my question, how do you basically catch and sense the numbers to reflect the market environment, also to ensure that Christian has a smooth start over your CEO?

I think anything you’ve been pushing on all the new dynamics or what you’re seeing in terms of customer conversations around the BIO-SECURE, it gives us more confidence that there’s no further downside risks. Definitely, [indiscernible] you go into the [dark bridge] [ph] many times in terms of how we got that €300 million, the base business, biologics experience, profitability, our assumptions and milestones. Anything in particular that’s the series, I mean, is there everything, but can you just move us through exactly where that shortfall comes because it feels your revenue or like, it’s not hugely different to where the market currently is. Lastly, maybe for Iris, when speaking about Evotec with potential investors, they always raise the concern that regulatory risks given the actions of the prior CEO.

When can we draw a line, when do you expect to hear from [Bob Binn] [ph], whether they’re applying that this really was the action of the [bad option] [ph], or that he missed around, or then they could send that out to systemic factors? So could you address the regulatory risk concerns that often comes up when discussing Evotec with investors? Thank you.

Volker Braun: Okay. So the first set of questions I think will be covered jointly by Matthias and Laetitia, and Iris will then cover the regulatory question. Hey, Peter, greetings. We must admit the voice line was hard to get all the details. We will start, and please feel free to follow-up with questions. I mean, it’s an important discussion, so please bear with us. I think that at the heart of the question we heard, of course, are we basically suggesting €100 million, and what happened basically in multiple ways? So let’s maybe restate a couple of assumptions. Number one is, we see uncertainty at this point of time, given what we have observed from that review. And yes, we want to give the new CEO a chance to review where we stand in the business.

And so, yes, that’s why we are actually giving only qualitative guidance at this moment of time. Ballpark-wise, I think you’re right, level-wise. I mean, that’s what we are signaling in terms of €100 million and upwards, but we give qualitative guidance at this moment of time. The underlying big question is, of course, what happened. Now, I think softening of other more transactional parts in the business, we started articulating in Q3. I think in the November discussion, we had very particular pointed out development, and that has two, three drivers. That was, of course, coming back out of the effects of the cyber-attack most hardened, it’s hardest in the GMP area. There was also part of a very bad biotech environment where we basically see a hit on our transactional business so and that was a bit overshadowed by the business coming back as a hockey stick after the recovery.

So we see the full effect in Q1 and that’s why I’ve been trying to outline the distinction between the high demand for our strategic, we now more and more call the pipeline co-creation offering. We see recovery and we are clear in the game with a very specific value proposition, and I give you one green shot that’s our INDiGO offering, where we provide end-to-end development offerings for biotech and see green shots, but we see also at this moment of time given market and given that situation high uncertainty plus CEO. That’s basically the answer why we give that qualitative guidance at this moment of time. Laetitia any additional comments or Peter come back if we missed nuances, because again it was a little bit hard to hear before we moved to Iris.

Peter Verdult: I’ll get back in the queue. And I’ll come.

Volker Braun: Thank you.

Iris Löw-Friedrich: Yeah. Peter, thanks for the regulatory question. So at this point in time we have no regulatory action ongoing, no inquiry, no action against the company. So on our side it’s all clean. Of course, I cannot speak on behalf of the regulator, so your question around timeline is something that is out of our control and that’s why I can’t comment on behalf of Evotec for this.

Peter Verdult: Thank you.

Volker Braun: Next question, please.

Operator: And the next question comes from Charles Weston from RBC. Please go ahead.

Charles Weston: Hello, thanks for taking the questions. I wanted to dig into something I guess a bit similar. It was only around 3 months ago that you reiterated the 2025 expectations. So can you just help us explain how the market has evolved literally in just the last few months to make you sort of change your view and become more cautious on that? Can you perhaps give us some examples of things that maybe have happened or haven’t happened over the last few months that have led you to change that view? And then you mentioned it was partly to do with trading and you talked about soft demand and biotech demand and biotech funding, but you’ve also talked about pricing pressure. So could you comment a bit on the competitive dynamics?

And then, lastly, at the lower end of the revenue guidance essentially no growth in the business, overall, if we add back the €70 million of lost revenues for Q2. So we sort of reset that base. Alternatively, we could look at this as a significant decline in the non-Just-Evotec Biologics business. So can you help us just by perhaps giving us some numbers and guidance around how much of the business you classify as transactional and how much is sort of more value add, and perhaps out of the revenue growth that you’ve told us kind of what the dynamics might be in those two businesses, how much could transactional be down in 2024?

Volker Braun: I think the question one and two will be answered by Matthias. And on transactional business, revenue share, I think that goes with Laetitia.

Matthias Evers: Charles, thank you. This is, of course, a very important question, and let me try to answer it in a simple way from two sides. And I start with the backend of your question, because you’re saying, is that de facto a decline, including the €70 million. We talked about it as an estimated effect or revenue loss from cyber. I think, first, let me turn around that statement a bit and say, we basically, in 2023, we delivered revenue growth more or less with a highly impacted quarter operationally. So we delivered growth. It’s too simple to say with 9 months, but for simplicity sake, with a loss quarter, we delivered growth. Now, to transition back to the new base, it’s a little bit harder than just saying our operations are back, because particular in development, and in the cyber-attack business, we have to basically regrow the sales pipeline.

And I mean, it’s like we lost a little bit the momentum and we see the build-up, but it will take some time. So we are not giving up the numbers. We are not giving up the demand, but it will easily take 6, 9 months to rebuild that momentum. So we cannot just switch the business back on. It’s particularly relevant and also in the very fast moving transactional cyber techs business, which is our ADME-Tox solution. So I want to acknowledge your point, because if we let the numbers speak, it’s of course, if you would include the €70 million, a much more moderate growth, but we see it as significant double-digit growth versus our 2023 base, because we have to rebuild that momentum. Your first part of the question, what is moving, what is shifting and the need for examples?

So first of all, we see a bias market dynamic. What is that? We see less incoming requests, so there’s less demand. Why is that? 40% of our business were biotech. Now, if you look at the first funding event, so new biotechs is basically back to 2014-2015 levels. Many analysts call in 2023, the worst year in biotech, and that effect is visible for us. So we have seen the share of biotech from roughly 40% going down to 34%, and that is, of course, one contributor. Second contributor, in a world where, of course, constrained in share price pressure, I think the procurement dynamics are more significant. So, yes, there is price pressure. We hold up well. Our win rate is significant, but the effort to win, it takes longer. So there are slower conversions.

So we would talk a bit more about deceleration of our business versus losing, while there is competitive pressure on price points. That together leads us to a very strong conviction that we get basically continuous double-digit growth, but we don’t see fully the point just to switch back to €70 million and start from a larger base. Hopefully that addresses those point, Charles, and then I give it further to Laetitia.

Laetitia Rouxel: And to answer your question on the share of our business on the transactional business part, it reflects an average of 20% currently of the business, which is a bit more under pressure if you want to have the direction. And I would say it’s offset by the other direction coming from Just-Biologics, which is growing shares in our 2024 revenue equation to be closer to the same representation of 20%.

Charles Weston: Thank you, Laetitia. Yes. So 20% could be down, potentially down substantially, Just-Biologics up substantially, and then the rest of sort of execute and innovate could be up.

Volker Braun: To be very clear, I mean, you can assume a similar growth trajectory also to next year for Just-Evotec Biologics, as you have seen.

Charles Weston: As a percentage?

Volker Braun: I make a qualitative statement, a similar ballpark growth rate.

Charles Weston: Okay. Thank you.

Operator: And the next question comes from Michael Ryskin from Bank of America. Please go ahead.

Michael Ryskin: Thanks, sir. Thanks for taking my question. I want to follow-up a little bit first with something on the underlying market conditions. I heard you that 2023 was a challenging year, and that funding still remains low, especially for biotechs, but I think also where we’re actually hearing early commentary of improving market conditions already of more proposals, more requests for outsourcing, because 1Q was a very good quarter. So that’s giving people some confidence that 2024 is a recovery year. It seems like you’re still a little bit more cautious. Is there any reason you’re not seeing some of those proposals and some of that requests done yet? Is it a real way to put what you’re talking about in terms of getting the business back on track? And if that’s the case, what gives you confidence that this isn’t a permanent share shift or share loss?

Matthias Evers: Thank you for the question. It’s very good and takes another lens at the market. So we hear that as well and I talked a little bit about green shots. We are indeed a little bit more careful. So we observe, I mean, if I’m a little bit more specific than before in terms of [seed drones] [ph]. We see an improved climate and there are new entities being formed and we see requests. Now do we see an uptick on Series A, Series B already? No, I think the mass and the market intelligence is very clear on that. So do we see a big pharma acquisitions as access points for biotech? Absolutely, yes. Do we see external outsourcing ideas also? But in aggregate and given the scale of our business we are indeed a little bit more careful, because we also sometimes feel there’s a little bit of wishful thinking on very early signals and that’s the last thing we want to do.

So we want to be very transparent on the demand logic of our business, which I think we summarize here strong demand on strategic parts, some more deceleration or, call it, harder conversion on our transactional part and this allows me also to very clearly repeat that high double-digital growth, similar growth for our Just-Evotec Biologics business, where we rather face the topic of capacity constraints more than anything else.

Michael Ryskin: Okay. All right. That’s helpful. And then my follow-up question is on the right sizing that you talked about, the reset of profitable growth. You talked about annualized EBITDA improvement of greater than €40 million over time. Could you provide any more clarity on where you’re doing some of that right sizing? You talked a little bit about trimming the unpartnered R&D, but €40 million is a pretty meaningful improvement in EBITDA. So any particular areas, any particular product offerings, that would be helpful. Thanks.

Volker Braun: Okay. Laetitia will take that question.

Laetitia Rouxel: So regarding the optimization cost structure that we have in mind the €40 million we share today with you, I would be a bit more precise is not less than €40 million, it’s above €40 million and it’s an annualized figure. So, obviously, we will not be able in 2024 to generate the full scope of those savings, but this is expected for 2025 in full. So, I think, it answers your first question when we will get this amount in the financial, so expect a full impact in 2025, and having in 2024, we are working with internal and external stakeholders to fine-tune and we come back in the mid-year results with you to go with more precise numbers. But, of course, we will have factored some of those savings already this year.

Then coming on the area we are looking at in – and I will repeat a little bit what we said just before it’s one around the organizational structure and the operating model that we have that now we are folding the segments we get more efficiency. It doesn’t change anything on the quality of what we deliver to our customers. It’s really internal optimization to be more optimized in what we deliver from a cost perspective and efficiency overall for our people. The second area is around the footprint and the capacity optimization. Of course, it’s really a topic that we are looking at in the light of what’s the market dynamic and we are obviously looking at matching our current operations and capacities with what the market dynamic is.

But of course, it doesn’t jeopardize any of the contracts we have currently that we have capacity to deliver, of course. And then the other area, so we are looking at is around the enabling function efficiency. And there you have different part of the exercise, I mentioned the procurement area, which is a low-hanging-fruit. I would say relatively simple topic. It’s a non-people topic. But we have really to make that efficient this year. And, I think, it’s really something that will generate already in 2020 for some savings. So it’s on the part of the non-people related. And then, I would say related to our organization, the footprint and the capacity optimization as much as well as the enabling function efficiency organization will come with people reduction overall and hiring plan review based on the exercise and the review we are currently running.

So I would say it falls into buying, or buying power, or buying costs that we want to optimize our footprint, that we also some fixed cost on our footprint that adapted at the current situation and people cost. I would say that would be around those three main areas that we see the savings coming from.

Michael Ryskin: Okay. All right. Thank you.

Operator: The next question comes from Jacqueline Kisa from TD Cowen. Please go ahead.

Jacqueline Kisa: Hi, this is Jacqueline Kisa on for Steven Mah at TD Cowen. Thank you for taking the questions. The BIO-SECURE Act previously named companies like WuXi Biologics as companies of concern. Has this impacted business development discussion with your customers and if so, have those customers been across the board or more with emerging biotech? And then with regards to your JPOD facility, could you update us on the current operating capacity of the facility and do you expect to have the capacity to take in new customers in the event there is a shift from WuXi? And then finally, when can we expect the operating JPOD facility to reach scale? Thank you.

Volker Braun: All three questions are directed to Matthias.

Matthias Evers: Okay, totally. And Steve, in representation, thank you for the question. BIO-SECURE, you might have seen quotes from us in a recent endpoints article, and I would start there, that we say we feel there are globally respected companies. I mean, the companies you mentioned, but we are ready to serve partners with our global footprint, with a footprint in the U.S. and in Europe. And we see a shift in discussions. I think more pronounced on our Just-Evotec Biologics on the biologics front, where I think we get more RFI’s interest exploration, so it’s early days, but we see a marketable shift. It’s hard to pinpoint exactly, BIO-SECURE versus frankly a completely validated technology, where partners are convinced about our cost differential in terms of COGS, our high quality and high flexibility.

It’s of course a mix of these factors, but we feel we see a notable shift. When it’s on the discovery and development side in our core business, it’s early days, but we see, I would say we are carefully optimistic also on the big pharma side. So with the U.S. players, with big exposure to Asia, that there’s a slow process and we are ready to serve them. Now, when it comes to JPOD particularly, and in terms of new capacity. So first of all, I’m happy to report that we are of course fully on track to launch our JPOD 2 in Toulouse. I think we are planning for a grand opening in September and this will add substantial capacity. And yes, we are ready to serve new partners, absolutely, because we want to bring in molecules and bring in molecules quickly to commercial stage onto our platform.